Novo Nordisk A/S
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 444.82 | 20,000 shares | |||||
| DKK 467.88 | 10,000 shares | |||||
| DKK 444.59 | 10,000 shares | |||||
| d) | Aggregated information
| 40,000 shares DKK 18,021,100 | ||||
| e) | Date of the transaction | 2025-05-07 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
Max Ung
+45 +45 3077 6414
mxun@novonordisk.com
Company Announcement No 15 / 2025
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Meeting Professionals International (MPI)9.5.2025 22:01:46 CEST | Press release
Registration open for MPI’s WEC 2025 in St. Louis; Registrants unlock mystery guest for the closing party
DP World9.5.2025 20:04:00 CEST | Press release
DP World Signs Agreement to Launch $760M Port & Free Trade Zone in Dominican Republic
Syensqo SA9.5.2025 17:45:00 CEST | Press release
Syensqo announces the cancellation of repurchased shares
Bavarian Nordic A/S9.5.2025 17:30:00 CEST | Pressemeddelelse
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
Bavarian Nordic A/S9.5.2025 17:30:00 CEST | Press release
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom